Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Feb
04
Today In Oncology
Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
World Cancer Day 2026 UICCs Campaign United by Unique
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
American College of Surgeons Publishes Annual NCDB Report
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo